✦ LIBER ✦

New players in ovarian cancer

✍ Scribed by Alessandro Bovicelli; Giuseppina D'Andrilli; Antonio Giordano

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 94 KB
Volume: 226
Category: Article
ISSN: 0021-9541
DOI: 10.1002/jcp.22662

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Ovarian cancer is the leading cause of gynecologic cancer mortality worldwide. The aim of this review is to highlight the most recent studies regarding ovarian cancer pathogenesis and the new therapeutic approaches against this insidious disease. We focus on the relevance of some cell cycle genes, transcription factors, and microRNAs in the carcinogenesis of ovarian cancer as well as on a new hypothesis for therapy using histone deacetylase inhibitors. We also report recent studies regarding some mechanisms of chemoresistance, a major obstacle in the treatment of ovarian cancer. Together these studies can improve our knowledge of ovarian cancer tumorigenesis and diagnosis providing new tools to hopefully defeat this deadly disease. J. Cell. Physiol. 226: 2500–2504, 2011. © 2011 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Prophylaxis in ovarian cancer

✍ Hugh R. K. Barber 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 578 KB

It has been shown that women who have taken the oral contraceptive pill for 4 or 5 years decreases the incidence of ovarian cancer by approximately 40%. It is estimated that the oral contraceptive pill can prevent approximately 1500 ovarian cancers each year. The postmenopausal palpable ovary syndr

Centrosome abnormalities in ovarian canc

Centrosome abnormalities in ovarian cancer

✍ Lih-Ching Hsu; Malathy Kapali; Julie A. DeLoia; Holly H. Gallion 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 254 KB

## Abstract Centrosome abnormalities have been found in various cancer types and are thought to be involved in early development of cancer and/or progression. The contribution of centrosome abnormalities to ovarian tumorigenesis has not been previously evaluated. We sought to determine whether cent

Hereditary ovarian cancer in Poland

✍ Janusz Menkiszak; Jacek Gronwald; Bohdan Górski; Anna Jakubowska; Tomasz Huzarsk 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 81 KB

There is increasing evidence that hereditary factors play a greater role in ovarian cancer than in any of the other common cancers of adulthood. This is attributable, to a large extent, to a high frequency of mutations in the BRCA1 or BRCA2 genes. In Poland, 3 common founder mutations in BRCA1 accou

Multidrug resistance in ovarian cancer

✍ Antonio Fojo; Thomas C. Hamilton; Robert C. Young; Robert F. Ozols 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 687 KB

The development of acquired resistance has limited the effectiveness of chemotherapy in the treatment of ovarian cancer. Experimental model systems were developed to study the mechanisms associated with primary resistance to chemotherapeutic agents and broad cross-resistance (multidrug resistance) w

Chemosensitivity testing in ovarian canc

Chemosensitivity testing in ovarian cancer

✍ Bernd-Uwe Sevin; James P. Perras; Hervy E. Averette; Daniel M. Donato; Manuel Pe 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 781 KB

Promising new therapies in the treatment

Promising new therapies in the treatment of advanced ovarian cancer

✍ Carolyn D. Runowicz; Abbie L Fields; Gary L. Goldberg 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 599 KB

Advanced stage ovarian cancer is the most lethal gynecologic cancer. Despite initial response rates of 60-80'/0 with platinum-based chemotherapy, more than 75% of women with this malignancy die of complications associated with this disease. There is a pressing need to find new chemotherapeutic agent